Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965914 | 0.87 | CES1 (0.61) | MAPTALDH1A1LMNAGAATDP1 | |
| SCHEMBL12920471 | 0.87 | POLB (0.59) | MAPTCA1CA2ALDH1A1LMNA | |
| SCHEMBL8643785 | 0.87 | CA12 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL967450 | 0.87 | MEN1 (0.56) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL27741918 | 0.87 | MEN1 (0.56) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL968140 | 0.85 | LMNA (0.59) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL968120 | 0.84 | HDAC3 (0.54) | MAPTCA1CA2ALDH1A1LMNA | |
| SCHEMBL5055409 | 0.82 | MAPT (0.55) | MAPTHPGDCA12CA1CA2 | |
| SCHEMBL11976998 | 0.82 | ALDH1A1 (0.64) | MAPTHPGDCA12CA1CA2 | |
| SCHEMBL16750533 | 0.79 | EPHX1 (0.60) | ALDH1A1LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024329-B1 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2013-07-31 | — | — | EP | claimed |
| US-7868046-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2011-01-11 | — | — | US | claimed |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2010-06-17 | — | — | US | claimed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | claimed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | claimed |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2023-05-18 | — | — | US | disclosed |
| US-11453715-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3848046-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | New York University (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210009664-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3441474-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E | UNIV NEW YORK (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2019-08-15 | — | — | US | disclosed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | disclosed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453715-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | MAPT 4824/4885HPGD 2349/4885CA12 4163/4885 |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | CCR2, CXCR2, CXCR4 | MAPT 4276/4885HPGD 792/4885CA12 4056/4885 |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | MAPT 4824/4885HPGD 2349/4885CA12 4163/4885 |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | MAPT 4824/4885HPGD 2349/4885CA12 4163/4885 |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | CCR2, CXCR2, CXCR3 | MAPT 4348/4885HPGD 550/4885CA12 3876/4885 |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | MAPT 4824/4885HPGD 2349/4885CA12 4163/4885 |
| US-20210009664-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | MAPT 4824/4885HPGD 2349/4885CA12 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.